Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,375 across all filing types
Latest filing 2020-07-30 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON THE UNAUDITED MAJOR OPERATIONAL DATA OF THE SECOND QUARTER OF 2020
Regulatory Filings Classification · 95% confidence The document is an announcement by Yanzhou Coal Mining Company Limited regarding unaudited major operational data for the second quarter of 2020. It contains preliminary operational data such as production and sales volumes for coal and coal chemicals, but it is explicitly stated as unaudited and preliminary. The document is relatively short (2876 characters) and does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is more of an operational update announcement rather than a full financial report. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories and is not a full report itself.
2020-07-30 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2019
Environmental & Social Information Classification · 100% confidence The document is titled '2019 Environmental, Social and Governance Report' and contains detailed sections on environmental, social, and governance topics such as corporate social responsibility policy, stakeholder engagement, environmental management, and social development. It explicitly states it is the second ESG Report for the year ended December 31, 2019. The content focuses on non-financial performance related to ESG factors rather than financial results or corporate governance rules. There is no indication that this is an announcement or a brief summary; the document length is substantial (15,000 characters) and contains substantive ESG content. Therefore, the document fits the category of Environmental & Social Information (SR).
2020-07-24 English
VOLUNTARY ANNOUNCEMENT - U.S. ORPHAN DRUG DESIGNATION FOR THE ANTI-PD1 ANTIBODY CS1003
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the U.S. FDA granting orphan drug designation to their drug candidate CS1003. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. It is a corporate announcement about a regulatory milestone related to drug development. The document length is 7,212 characters, which is relatively short and typical for an announcement. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is clearly an announcement of a regulatory or clinical development milestone, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-07-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER BLUEPRINT MEDICINES ANNOUNCED SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA FOR PRALSETINIB FOR THE TREATMENT OF ADVANCED RET MUTANT AND RET FUSION-POSI
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding their partner Blueprint Medicines' submission of a New Drug Application (NDA) to the U.S. FDA for a cancer treatment drug. It contains no financial statements, no detailed financial analysis, no regulatory certifications, no meeting materials, no voting results, no management or board changes, no earnings data, and no legal proceedings. It is an announcement of a significant corporate event related to drug development and regulatory submission. The document is about a regulatory or corporate announcement rather than a financial report or detailed investor presentation. Given the content and length (7,313 characters), it is not a report publication announcement or a certification. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2020-07-20 English
VOLUNTARY ANNOUNCEMENT - GRANT OF RESTRICTED SHARE UNITS AND PROPOSED ISSUE OF SHARES PURSUANT TO THE POST-IPO RSU SCHEME
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the grant of restricted share units (RSUs) and the proposed issue of shares pursuant to the Post-IPO RSU Scheme. It discusses details about the RSU awards, vesting schedules, and compliance with listing rules. There is no indication that this is a full financial report, audit report, earnings release, or any other detailed financial or management report. Instead, it is an announcement related to share issuance and equity compensation schemes. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share issuances related to RSU schemes. The document length is over 5,000 characters and contains substantive information about the share issuance plan, not merely a brief notice or a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2020-07-16 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE SECOND QUARTER OF 2020 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANZHOU COAL MINING COMPANY LIMITED
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding the production and sales volume for the second quarter of 2020 of an overseas subsidiary, Yancoal Australia. It provides summary data on coal production and sales volumes but does not contain detailed financial statements or comprehensive analysis. The document is relatively short (2507 characters) and refers readers to the full reports published by Yancoal Australia on the ASX and HKEX websites for further details. This indicates that the document is an announcement of operational data rather than a full financial report. It does not fit the criteria for an Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis. It is also not an Earnings Release (ER) since it does not present key financial highlights or earnings results. Given the nature and length of the document, and the fact it is an announcement of production and sales volume data, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-07-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.